Ignite Creation Date:
2024-05-06 @ 1:19 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03988036
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2019-03-07
Brief Title:
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype Keyriched-1
Sponsor:
West German Study Group
Organization:
West German Study Group
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-18
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-31
Completion Date Type:
ACTUAL
First Submit Date:
2019-03-07
First Submit QC Date:
June 14 2019
Study First Post Date:
2019-06-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-12
Last Update Post Date:
2023-05-15
Last Update Post Date Type:
ACTUAL